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Denkbeeldige Wereld: The New Dutch Guidelines for Economic Evaluations in Healthcare 
Paul C Langley, PhD 
Adjunct Professor, College of Pharmacy, University of Minnesota 
  
Abstract 
In 2016 the Dutch National Health Care Institute (Zorginstituut Nederland) published a new guidance for economic evaluations in 
healthcare to support reimbursement decisions. These Guidelines update and replace three previously published guidelines covering 
pharmacoeconomic evaluation, outcomes research and costing. The purpose of this commentary is to consider the merits of these new 
Guidelines from the perspective of modeled claims which meet the standards of normal science: credibility, evaluation and replication 
in the treatment of target patient populations. In evaluating the merits of the Guidelines the focus will be on the requirement for 
submissions to follow reference case standards where lifetime-cost-per-QALY claims are the preferred outcome measure. The 
assessment points out that in adhering to a reference case standard, the Dutch Guidelines, in common with those in the UK, Ireland 
and New Zealand, fail to address the fundamental question of claims assessment. Rather, in relying upon the reference case imaginary 
world (denkbeeldige wereld) to inform decision makers, the possibility of evaluating claims and generating feedback to decision makers 
on comparative effectiveness is put to one side. We have no idea as to whether the claims are right or even if they are wrong. Hopefully, 
future versions of the guidelines will address this issue and focus on a rigorous program of claims assessment. 
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Introduction 
Over the past 25 years, recommendations and standards for 
assessing the merits of competing health care interventions 
have focused on informing decision makers through the 
construction of imaginary worlds (denkbeeldige wereld). The 
new Dutch guidelines for economic evaluations in healthcare, 
published in 2016, follow in this tradition 1 . In common with 
countries such as the UK, Ireland and New Zealand, together 
with the proposed EUnetHTA guidelines for the European 
Union, the focus is on a reference case; a construct that 
mandates a lifetime perspective with claims for competing 
interventions expressed in cost-per-quality adjusted life years 
(QALYs) 2 3 4 5.  
 
Previous publications and formulary evaluation commentaries in 
this series have made clear that in putting to one side a 
commitment to the standards of normal science, where modeled 
claims or hypotheses are credible, evaluable and replicable, 
decision makers in health care have a limited evidence base for 
formulary decisions 6 7 . Rather than putting claims for competing 
or new interventions in a framework that supports evaluation and 
feedback in a meaningful time frame, groups  
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such as the International Society for Pharmacoeconomics and 
Outcomes Research (ISPOR) and, in the UK, the National 
Institute for Health and Care Excellence (NICE) have supported 
reference case cost-per-QALY modeling as the recommended 
submission standard 8 9 . A lifetime cost-per-QALY model is not 
designed to generate evaluable claims. It is a construct that is 
defended by its sufficient correspondence to reality. Validation 
focuses on the core model and its assumptions. Whether or 
not the model can support evaluable claims and whether or 
not these claims could ever be evaluated is irrelevant. 
 
In rejecting the standards of normal science, advocates of 
models that are intended to ‘inform’ decision makers in health 
care systems (whatever that means) rather than establish a 
practical research program, effectively put to one side a 
commitment to standards that have been in place since the 
seventeenth century in favor of what may be described as 
pseudoscience: intelligent design rather than natural selection 
10. In an effort to avoid this characterization, guidelines have 
been proposed by the Program in Social and Administrative 
Pharmacy at the University of Minnesota that put to one side 
imaginary constructs in favor of credible, evaluable and 
replicable claims; claims which apply equally well to clinical 
outcomes as well as those for comparative cost-effectiveness 
and budget impact 11. Formulary submissions are supported by 
protocols to detail how the claims are to be evaluated and 
reported.  
 
The purpose of this commentary is to consider the merits of 
the new Dutch Guidelines from the perspective of modeled 
claims which meet standards of normal science: supporting 
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credibility, evaluation and replication in claims for treatment 
effect. In evaluating the merits of the new Guidelines the focus 
will be on the requirement for submissions to follow strictly 
reference case standards where lifetime-cost-per-QALY claims 
are the standard outcome measure. Given the limitations 
inherent in the reference case paradigm, recommendations 
are made for reformulation of the Guideline so that claims 
assessments conform to the standards of normal science.  
 
Structure of the New Guideline 
The purpose of the new Guideline is to provide a framework to 
assess whether there is sufficient evidence to support 
reimbursement for a drug. The new Guideline comprises five 
core sections. These are: 
 
• Framework of the Economic Evaluation 
• Method: Analytic approach 
• Input Data 
• Reporting 
• Budget impact analysis 
Framework of the Economic Evaluation 
Before an economic evaluation is undertaken an evaluation 
framework and design should be agreed. The framework must 
encompass the aspects described below in reporting the 
evaluation with a justification for the choices made. The 
elements of the framework are: 
 
• Objectives: a statement of the decision making 
problem the evaluation is to solve 
• Users: the future users of the evaluation to include 
the National Health Care Institute, health insurers and 
health facilities 
• Perspective: to include all relevant societal costs and 
benefits  
• Research question: to be formulated in accordance 
with PICOT criteria: (i) Patient or target population; 
(ii) intervention to be assessed; (iii) comparator or 
control; (iv) relevant outcome measure(s) 
• Relevant time span for measuring effects and costs  
In the case of the control or comparator therapy this should be 
the standard of care in usual practice and must reflect most 
recent national or international guidelines or standards, to 
include palliative or supportive care. As far as outcome 
measures are concerned, QALYs are the standard measure. 
This does not mean that other outcomes such a life years lived 
or patient reported outcomes (PRO) are put to one side; 
merely that they are an adjunct to the core claims expressed 
as cost-per-QALY. For the Guideline it is ‘imperative’ to follow 
the reference case (see below) which means that the 
perspective of the economic evaluation is societal, taking into 
account all relevant societal costs and benefits irrespective of 
who bears them or who benefits from them. 
 
Guideline Reference Standard 
The principal objective of the new Guideline is to improve the 
comparability of economic evaluations in the Netherlands. 
This is accomplished by establishing a reference case which 
sets the minimum standard. While there may be some 
deviations from the reference case, alternative approaches 
cannot replace the required standards. These are: 
 
• Submissions should adopt a societal perspective 
• Submissions should focus on a Dutch population 
• Interventions should be compared to Dutch standard 
or usual care 
• Assessments should take a lifetime perspective  
• Required analytical framework should be cost utility 
analysis 
• Costs and effects should be discounted at 4% and 1% 
respectively 
• Uncertainty and sensitivity should be evaluated 
through univariate, probabilistic sensitivity and 
scenario analysis 
• Costs should include those appropriate to the 
healthcare sector, patient and family and other 
sectors 
• Where appropriate productivity losses should be 
captured using the friction cost method 
• Wherever possible reference prices should use the 
Manual for Cost Research 
• Outcomes should be expressed as QALYs utilizing at 
least the EQ-5D-5L with Dutch valuation and, 
whenever relevant, life years gained 12 
• Results should be expressed as (i) total costs and 
effects; (ii) incremental costs and effects; and (iii) 
incremental cost-effectiveness ratios 
• Uncertainty and sensitivity results should be 
captured by (i) univariate sensitivity analysis with a 
Tornado diagram and table; (ii) scenario analysis as a 
table; and (iii) probabilistic sensitivity analysis as a 
CE-plane and cost-effectiveness acceptability curve 
Decision Framework and Model Validation 
A decision framework is central to the analytic approach 
mandated in the reference standard. While a developer may 
attempt to justify an empiric approach where all relevant costs 
and benefits are collected within one clinical study, the model-
approach is clearly the preferred option. The choice of decision 
framework will be influenced by the research question and 
medical decision. The appropriate technique has to be justified 
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in the choice of decision trees, state-transition models, 
discrete event simulations or dynamic transmission models. 
 
Once a decision framework has been selected, outcome and 
cost data are required to be discounted if the time frame is 
greater than 12 months. The next steps are: (i) to determine 
the degree of uncertainty for costs, outcomes and cost 
effectiveness ratios; and (ii), and to quantify the consequences 
of the uncertainty and the value of additional research to 
reduce uncertainty. The degree of uncertainty can be captured 
by uncertainty analyses as detailed in the reference case while 
the value of additional research can be assessed through value 
of information analysis.  
 
The Guideline requires prior validation of the decision model. 
This is to ensure that the model results are ‘usable, reliable and 
credible’. The validation should encompass the conceptual 
model, the input data, the software to support the model and 
the model outcomes. Optimal reporting on the validation 
process is achieved by: (i) using a purpose-designed checklist 
and (ii) by providing a systematic representation of the 
validation steps. The example given of a tool to achieve these 
objectives is the AdViSHE toolkit13. The limitations of this 
toolkit have been explored in a recent commentary in this 
series 14.  
 
Model Input Data and Reporting 
Where an economic evaluation is undertaken in the context of 
a randomized clinical trial (RCT) or observational study, the 
effectiveness input data are derived from the study possibly 
supplemented by other relevant publications. For a model-
based study the input data should be grounded on all relevant 
studies that meet required standards. In both cases literature 
searches and systematic reviews should conform to accepted 
standards, where search strategies, the ranking of individual 
studies and outcomes are documented together with reports 
on individual studies. Where necessary indirect comparisons 
should be undertaken to generate comparative effect claims. 
 
All categories of societal costs should be identified. These 
should follow the guidance set down in the Manual for Cost 
Research and the reference prices for common units. Prices 
and volume of all cost components should be reported 
separately. 
Quality of life should be consistently measured with the EQ-
5D-5L with Dutch reference values. Alternative measures can 
be added to the reference case. Even if the EQ-5D-5L is 
considered to lack sensitivity in a target population it should 
still be used. If valuations of quality of life are derived from the 
literature the submission should report: the questionnaire or 
valuation method, nationality of respondents and patient or 
societal valuations. 
Budget Impact Analysis 
The budget impact analysis (BIA) should follow the ISPOR 
standards to estimate the difference in expected expenditure 
between a reference scenario and a scenario in which the new 
or optimized intervention is accepted and disseminated. Key 
elements are: (i) perspective, which in the Dutch case is the 
national government; (ii) the time horizon where a 3-year 
minimum is recommended; (ii) the dynamics of 
implementation; (iv) the items of expenditure, volume 
measurement and valuation; and (v) reporting by budget 
period. 
 
Further Applications 
The Guideline also considers additional applications outside of 
those for the economic evaluation of pharmaceuticals. 
Consideration is given to the economic evaluation of: (i) 
prevention interventions; (ii) diagnostics; (iii) medical devices; 
(iv) long-term care; and (v) forensics. 
 
Overview   
The intent of the Guideline is to ensure, through a prior 
validation of the reference model, that the decision model 
results are ‘usable, reliable and credible’. At the same time, 
there is no requirement in the Guideline that the reference 
model results are ‘credible, evaluable and replicable’ in target 
patient populations. This is not an oversight. It is clear from the 
focus on the reference model standards, with the default 
standard of a lifetime model with outcomes expressed as 
incremental discounted cost-per-QALYs, that there is no 
intention that the claims generated by the model are to be 
evaluated. Rather the modeled or simulated claims is to be 
considered a ‘sufficient’ representation of the expected 
societal costs and benefits generated by competing 
pharmaceutical products. As long as the model meets the 
standards required then, in judging it sufficient, the outcomes 
claimed necessarily follow.  
 
Constructed Evidence 
Unfortunately, in the absence of claims that are evaluable and 
replicable, there is no assurance that they are ‘usable, reliable 
and credible’. To argue that they meet these standards, in the 
absence of any empirical evidence to support the claims, is to 
adopt a relativist position. For a relativist evidence is never 
discovered, only constructed within a particular social 
community 15.  In a community of health economists that 
accept a reference case paradigm to support claims for 
competing pharmaceutical products they would reject any 
arguments that one body of evidence is superior to another. A 
research program is not seen as one that generates new 
knowledge through claims evaluation and replication but one 
that is judged on its ability to persuade and mobilize 
community support for invented facts. Such a research 
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program puts to one side any notion of the progress of science, 
of the process through which new evidence overturns 
consensus views, in favor of rhetoric and authority. Reference 
case modeling is seen as the ‘gold standard’. 
 
Evaluating Credible Claims 
Rejecting the reference case does not mean that claims 
expressed in quality of life terms using, for example, the EQ-
5D-5L would be rejected out of hand because these data are 
not collected on a regular basis from patient encounters. In the 
Minnesota guidelines (and earlier guidelines proposed for the 
WellPoint (now Anthem) health system, the proposal was that 
when a manufacturer submitted an economic evaluation to 
support formulary listing, it should be accompanied by a study 
protocol that detailed how the claims for comparative product 
performance were to evaluated and reported back to decision 
makers. The timeframe was assumed to be relatively short 
(under two years) with the product provisionally accepted for 
formulary listing until evidence for the validation of clinical and 
cost-effectiveness claims could be assessed. 
 
Adherence and Persistence 
A puzzling feature of lifetime reference model claims is the 
neglect of adherence and persistence behavior. The new 
Guideline is no exception. Nowhere in the instructions for 
constructing the imaginary reference case world is there any 
guidance on including compliance behavior. This appears an 
odd oversight as the Guideline is explicit in the requirement for 
a default lifetime model. If this implies that the hypothetical 
patient cohort are persistent with therapy over their lifetime, 
this flies in the face of decades of accumulated evidence which 
shows that by the end of two years from an index 
prescriptions, probably less than one third of patients are 
persistent with therapy with an even smaller proportion 
maintaining a adherence at a clinically meaningful level. If this 
is the case, then to model competing therapies assuming full 
compliance over the lifetime of the patient cohort would seem 
pointless.  
 
Lifetime Costs 
A further puzzling feature is the assumption that current costs 
(corrected for discounting) remain unchanged over the 
lifetime of the hypothetical patient cohort. Again, this seems 
an odd assumption. In the US, for example, there is ample 
evidence for pricing strategies by manufacturers for ongoing 
semi-annual and annual price increases both over the patent 
of a drug and beyond. The price increases being accompanied 
by co-payment waivers, coupons and other discounts to 
maintain market share. In the case of disease modifying 
treatments (DMTs) in multiple sclerosis a recent study of the 
trend in annualized drug costs for nine DMTs from 1993 to 
2014 found changes ranging from 7.9%. to 35.7% 16.  Four of 
the DMTs had annualized cost increases greater than 20% and 
four in the range 13% to 16.8%. While these annualized 
changes were two to three time bigger than in other countries, 
the potential for annualized price increases together with 
possible price increases in direct medical costs should, 
presumably, be factored into reference case models. In the 
Dutch case, anticipated price increases should presumably be 
extended to other societal costs elements captured by the 
model.  
 
Pipeline Competitors  
It is unlikely, over the lifetime of a patient cohort, that there 
will be no therapies entering the market place to compete with 
and replace existing medications. In the reference case model 
this is not the case. Patients are assumed to remain with the 
indicated drug over their lifetime. Again, this flies in the face 
of evidence for drug turnover in target populations where 
patients are switched to new therapies. This switching may 
reflect a lack of response to the index drug in the treatment 
arm or may involve moving to a combination therapy. Again, 
this appears an odd assumption but one that is, unfortunately, 
driven by the focus on constructing evidence to establish 
credibility rather than on a more practical perspective of 
evaluating claims for feedback to physicians and formulary 
committees.  
 
Next Generation Sequencing 
The likelihood of competitor therapies and therapy 
combinations is also made more likely by the introduction of 
next generation sequencing (NGS) where assay platforms will 
recommend linking sub-groups of patients defined by 
mutation clusters to monotherapy or combination therapies 17 
18. An obvious application is in late stage cancer but there will 
be applications earlier in the treatment pathway. In these 
scenarios there will be a premium place on tracking evaluable 
claims and reporting in real time to clinicians and health 
system decision makers on clinical outcomes and resource 
utilization. If a disease area or target tumor group is 
characterized by a distribution of patients by mutation cluster 
than a simplistic reference case model is hardly a viable basis 
for therapy choices when multiple pathways are involved and 
patients are individually selected for an assay driven 
intervention. 
 
Redrafting the Dutch Guideline 
The claim that the new Dutch Guideline represents a singular 
improvement (‘From Good to Better’) over the previous 
guidelines is debatable 19. Clearly, if health decision makers in 
the Netherlands believe that the construction of reference 
case imaginary worlds provide a viable constructed evidence 
base to support comparative assessments then that is the end 
of the debate. Any criticisms will no doubt be put to one side 
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even though, as noted above, to claim that the reference 
model is a sufficient representation of the decision 
environment seems odd when it makes no accommodation for 
adherence, persistence, new therapies and potential price 
increases. Perhaps it should be made explicit that in accepting 
the reference case paradigm as the standard for economic 
evaluations any the claims presented are immune to failure. 
With the reference case as the ‘gold standard’ it should be 
admitted that it is impossible and was never considered 
feasible or necessary to attempt to evaluate and even replicate 
competing product claims. 
 
If claims are to meet scientific standard for evaluation and 
replication, then there may have to be a reconsideration of the 
scope of the new Guideline. In attempting to take a societal 
perspective that encompasses all relevant social costs and 
benefits irrespective of who bears the cost or who benefits, 
the guideline may be overly ambitious. A more pertinent 
approach may be to ask what claims can be usefully evaluated 
and reported within a 2-year time frame? Should these claims 
be restricted to the healthcare system?  It seems absurd to 
create a decision framework that attempts to encompass all 
relevant social costs and benefits when there are no data, 
apart from those generated by an evaluation protocol, which 
would support a credible evaluation. On the other hand, it 
might be possible, within an observational study protocol to 
evaluate claims for patient and family costs, individual 
absenteeism and presenteeism costs and even costs incurred 
outside the healthcare system by municipal services. Claims 
made should recognize data limitations as well as the potential 
costs of data collection to support claims evaluation. If data are 
limited, then observational prospective studies may offer the 
most appropriate avenue for claims validation.  
 
Redrafting the Dutch Guideline would also give an opportunity 
to take explicit account of anticipated patterns of adherence 
and persistence with therapy. As noted above, over the 
proposed 2-year (or shorter) timeframe it is likely that up to 
possibly two-thirds of patients would discontinue or be non-
adherent with therapy. These patterns need to be factored 
into claims for product effectiveness. They also give a baseline 
for evaluating comparative claims for persistence and 
adherence behavior as part of the assessment protocol. 
 
Rejecting the reference case as the focus for modeling claims 
does not mean throwing the bathwater out with the baby. 
Many of the standards and processes detailed in the new 
Guideline will be relevant to the construction of short-term 
claims models. Just as the reference case modeled outcomes 
can be expressed as total costs and outcomes, incremental 
costs and outcomes and incremental cost-effectiveness ratios, 
so short-term claims can be expressed in these terms. The key 
is the specification of a claims assessment protocol detailing 
how the claims are to be validated and reported to decision 
makers. This does not mean that claims expressed in quality of 
life terms are necessarily excluded. It is up to the submission 
to make the case for quality of life in the assessment 
timeframe.   
 
Conclusions 
From the perspective of normal science, constructed evidence 
for product impact claims is not acceptable. Regardless of how 
decision modeling is defended by the application of validation 
standards, the treatment of uncertainty and the application of 
value of information techniques, in the last resort the model 
stands or falls on its ability to generate credible, evaluable and 
replicable predictions. The new Dutch guideline fails to meet 
this standard. If the guideline is to be seen as credible then it 
must abandon constructing model evidence in favor of 
evaluable and replicable claims for comparative product 
performance.  
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